FORA Capital LLC Takes Position in Halozyme Therapeutics, Inc. $HALO

Key Points

• FORA Capital LLC has acquired 27,160 shares of Halozyme Therapeutics, valued at approximately $1.73 million, during the first quarter of the year.
• Halozyme Therapeutics reported $1.54 earnings per share for the last quarter, surpassing analysts' expectations of $1.23, with a total revenue of $325.72 million.
• Insider trading activities include CEO Helen Torley selling 20,000 shares at an average price of $63.51, reducing her ownership in the company.

FORA Capital LLC bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 27,160 shares of the biopharmaceutical company's stock, valued at approximately $1,733,000.

Other institutional investors have also bought and sold shares of the company. Isthmus Partners LLC lifted its position in shares of Halozyme Therapeutics by 2.5% in the first quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company's stock valued at $439,000 after acquiring an additional 169 shares in the last quarter. OneDigital Investment Advisors LLC raised its stake in Halozyme Therapeutics by 1.7% during the 1st quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company's stock valued at $649,000 after purchasing an additional 175 shares during the period. Park Place Capital Corp lifted its holdings in Halozyme Therapeutics by 20.1% in the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock worth $69,000 after purchasing an additional 182 shares in the last quarter. Xponance Inc. boosted its stake in Halozyme Therapeutics by 1.1% in the 1st quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company's stock worth $1,190,000 after purchasing an additional 198 shares during the period. Finally, Bessemer Group Inc. grew its holdings in Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 207 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the completion of the transaction, the chief executive officer directly owned 733,719 shares of the company's stock, valued at $46,598,493.69. The trade was a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 80,000 shares of company stock valued at $4,532,600 in the last ninety days. 2.90% of the stock is owned by company insiders.

Halozyme Therapeutics Trading Up 0.5%

Shares of NASDAQ:HALO traded up $0.34 during trading on Monday, reaching $73.15. The company's stock had a trading volume of 1,163,957 shares, compared to its average volume of 2,229,040. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a 12 month low of $42.01 and a 12 month high of $74.07. The firm's 50 day simple moving average is $60.68 and its two-hundred day simple moving average is $59.28. The stock has a market capitalization of $8.56 billion, a PE ratio of 16.74, a price-to-earnings-growth ratio of 0.42 and a beta of 1.19.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.31. The company had revenue of $325.72 million for the quarter, compared to analysts' expectations of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The firm's revenue for the quarter was up 40.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Benchmark downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th. The Goldman Sachs Group started coverage on shares of Halozyme Therapeutics in a report on Thursday, July 10th. They issued a "neutral" rating and a $55.00 price target on the stock. Morgan Stanley increased their price objective on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the company an "overweight" rating in a report on Monday, August 18th. JPMorgan Chase & Co. lifted their target price on Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a "neutral" rating in a report on Thursday, August 7th. Finally, Wells Fargo & Company increased their price target on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a research note on Wednesday, May 7th. Four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $67.11.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.